hjk05
Joined 7 years ago
Joined 7 years ago
Data seems to suggest this, which is going to extreme lengths beyond “expert votes”. And is more akin to changing the rules at the last minute to avoid living up to the promises put out by the platform.
If this is not the case then perhaps you can release more data to illuminate the oddities highlighted by the article?
The really cool thing here is that they parse the excel formula in order to automatically “figure out” how they can perform the bootstrapping.
That said, if you want to now cancel it get in touch with their costumer service they’ll likely help you.
It’s a wired definition of milking a product to lower your take home year after year. The PBMs have rebates close to 70% they are literally making more on the drugs than both the companies producing them and the companies providing them through insurance. List prices are high because the people who own the consumer side of the market don’t care how high the prices go as long as they can set up rebates that increase their own profits.
Of cause you can just put systems and rules around your spreadsheet practices and start adding passwords and accompanying documentation of “what you must do when using this document”. But When you get into these situations it’s almost always a better decision to set up an actual system to handle your data.
You can’t have it both ways. Cheap alternatives are available. But yes newer main brand products are better in tons of ways, which is not surprising as they are culmination of decades of research. You can’t both claim there are no differences and than want those differences in the cheaper generics.